Kinugasa, Eriko
Igawa, Ken
Shimada, Hisaki
Kondo, Morihiro
Funakoshi, Satoshi
Imada, Naoki
Itami, Noritomo
Fukazawa, Naoki
Takubo, Ryoko
Kawata, Yuichi
Murota, Hiroyuki
Funding for this research was provided by:
Chugai Pharmaceutical
Article History
Received: 31 July 2020
Accepted: 8 March 2021
First Online: 22 March 2021
Declarations
:
: EK has reported receiving lecture fees from Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. KI has reported receiving lecture fees from Sanofi K.K., Tokyo, Japan. HS has declared that no conflict of interest exists. MK has declared that no conflict of interest exists. SF has declared that no conflict of interest exists. NImada has declared that no conflict of interest exists. NItami has declared that no conflict of interest exists. NF, RT, and YK are employees of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, which funded this research. HM has declared that no conflict of interest exists.
: This study was performed in compliance with the ethical principles based on the Declaration of Helsinki and the Good Clinical Practice Guidelines. Ethical approval was obtained from the institutional review board of each participating institution.
: Informed consent was obtained from all individual participants included in the study.